Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 4/20 | 0.53 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.53 |
| ▸ | SPHK1 | Q9NYA1 | 2/20 | 0.53 |
| ▸ | GMNN | O75496 | 1/20 | 0.53 |
| ▸ | POLB | P06746 | 1/20 | 0.53 |
| ▸ | THPO | P40225 | 1/20 | 0.53 |
| ▸ | MTOR | P42345 | 1/20 | 0.53 |
| ▸ | BLM | P54132 | 1/20 | 0.53 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.53 |
| ▸ | TP53 | P04637 | 1/20 | 0.53 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.53 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.53 |
| ▸ | MAPT | P10636 | 1/20 | 0.53 |
| ▸ | CETP | P11597 | 1/20 | 0.53 |
| ▸ | HTT | P42858 | 1/20 | 0.53 |
| ▸ | UBE2N | P61088 | 1/20 | 0.53 |
| ▸ | MEN1 | O00255 | 1/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.42 |
| ▸ | GPR84 | Q9NQS5 | 4/20 | 0.42 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28230195 | 1.00 | LMNA (0.53) | LMNACYP2D6SPHK1GMNNPOLB | |
| SCHEMBL28514544 | 1.00 | LMNA (0.53) | LMNACYP2D6SPHK1GMNNPOLB | |
| SCHEMBL28950325 | 1.00 | LMNA (0.53) | LMNACYP2D6SPHK1GMNNPOLB | |
| SCHEMBL28445764 | 1.00 | LMNA (0.53) | LMNACYP2D6SPHK1GMNNPOLB | |
| SCHEMBL2232628 | 1.00 | LMNA (0.53) | LMNACYP2D6SPHK1GMNNPOLB | |
| SCHEMBL1963677 | 0.98 | LMNA (0.52) | LMNACYP2D6SPHK1GMNNPOLB | |
| SCHEMBL1962699 | 0.98 | LMNA (0.52) | LMNACYP2D6SPHK1GMNNPOLB | |
| SCHEMBL18860790 | 0.96 | LMNA (0.50) | LMNACYP2D6SPHK1GMNNPOLB | |
| SCHEMBL27867632 | 0.96 | LMNA (0.50) | LMNACYP2D6SPHK1GMNNPOLB | |
| SCHEMBL21836273 | 0.92 | LMNA (0.50) | LMNACYP2D6SPHK1GMNNPOLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 29 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240067965-A1 | ORAL DELIVERY OF ANTISENSE CONJUGATES TARGETING PCSK9 | CIVI BIOPHARMA INC (US) | 2024-02-29 | — | — | US | disclosed |
| EP-4259799-A1 | ORAL DELIVERY OF ANTISENSE CONJUGATES TARGETING PCSK9 | Civi Biopharma, Inc. (US) | 2023-10-18 | — | — | EP | disclosed |
| WO-2022125913-A9 | ORAL DELIVERY OF ANTISENSE CONJUGATES TARGETING PCSK9 | CIVI BIOPHARMA, INC. (US) | 2023-06-08 | — | — | WO | disclosed |
| WO-2022125913-A1 | ORAL DELIVERY OF ANTISENSE CONJUGATES TARGETING PCSK9 | CIVI BIOPHARMA, INC. (US) | 2022-06-16 | — | — | WO | disclosed |
| EP-3914232-A1 | LIPID VESICLE FOR ORAL DRUG DELIVERY | F. Hoffmann-La Roche AG (CH) | 2021-12-01 | — | — | EP | disclosed |
| WO-2020152303-A1 | LIPID VESICLE FOR ORAL DRUG DELIVERY | F. HOFFMANN-LA ROCHE AG (CH) | 2020-07-30 | — | — | WO | disclosed |
| EP-3620519-A1 | USE OF ISOLATED MILK EXTRACELLULAR VESICLES FOR DELIVERING OLIGONUCLEOTIDES ORALLY | F. Hoffmann-La Roche AG (CH) | 2020-03-11 | — | — | EP | disclosed |
| US-10443058-B2 | Antisense oligomers targeting PCSK9 | ROCHE INNOVATION CENTER COPENHAGEN A/S (DK) | 2019-10-15 | — | — | US | disclosed |
| US-10370668-B2 | Manufacture of antisense oligomers and conjugates targeting PCSK9 | ROCHE INNOVATION CENTER COPENHAGEN A/S (DK) | 2019-08-06 | — | — | US | disclosed |
| EP-3406718-A1 | OLIGONUCLEOTIDE CONJUGATES | Roche Innovation Center Copenhagen A/S (DK) | 2018-11-28 | — | — | EP | disclosed |
| EP-2920307-A1 | ANTI APOB ANTISENSE CONJUGATE COMPOUNDS | Roche Innovation Center Copenhagen A/S (DK) | 2015-09-23 | — | — | EP | disclosed |
| EP-2920304-A1 | OLIGONUCLEOTIDE CONJUGATES | Roche Innovation Center Copenhagen A/S (DK) | 2015-09-23 | — | — | EP | disclosed |
| WO-2015071388-A1 | APOB ANTISENSE CONJUGATE COMPOUNDS | ROCHE INNOVATION CENTER COPENHAGEN A/S (DK) | 2015-05-21 | — | — | WO | disclosed |
| WO-2014207232-A1 | ANTISENSE OLIGOMERS AND CONJUGATES TARGETING PCSK9 | SANTARIS PHARMA A/S (DK) | 2014-12-31 | — | — | WO | disclosed |
| WO-2014118267-A1 | LNA OLIGONUCLEOTIDE CARBOHYDRATE CONJUGATES | SANTARIS PHARMA A/S (DK) | 2014-08-07 | — | — | WO | disclosed |
| WO-2014076196-A1 | ANTI APOB ANTISENSE CONJUGATE COMPOUNDS | SANTARIS PHARMA A/S (DK) | 2014-05-22 | — | — | WO | disclosed |
| WO-2014076195-A1 | OLIGONUCLEOTIDE CONJUGATES | SANTARIS PHARMA A/S (DK) | 2014-05-22 | — | — | WO | disclosed |
| WO-2006031461-A2 | PYRROLIDINYL GROUPS FOR ATTACHING CONJUGATES TO OLIGOMERIC COMPOUNDS | ISIS PHARMACEUTICALS, INC. (US) | 2006-03-23 | — | — | WO | disclosed |
| WO-2005113571-A2 | METHODS FOR THE DELIVERY OF OLIGOMERIC COMPOUNDS | THE UNIVERSITY OF NORTH CAROLINA AT CHAPEL HILL (US) | 2005-12-01 | — | — | WO | disclosed |
| WO-2004044141-A2 | CONJUGATED OLIGOMERIC COMPOUNDS AND THEIR USE IN GENE MODULATION | ISIS PHARMACEUTICALS, INC. (US) | 2004-05-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240067965-A1 | ORAL DELIVERY OF ANTISENSE CONJUGATES TARGETING PCSK9 | PCSK9, SCD5, PCSK7 | LMNA 572/4885CYP2D6 2462/4885SPHK1 553/4885 |
| US-10443058-B2 | Antisense oligomers targeting PCSK9 | PCSK9, PCSK7, PCSK6 | LMNA 199/4885CYP2D6 4600/4885SPHK1 491/4885 |
| US-10370668-B2 | Manufacture of antisense oligomers and conjugates targeting PCSK9 | PCSK9, PCSK7, PCSK6 | LMNA 194/4885CYP2D6 4416/4885SPHK1 500/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.